At present, RainMed Medical’s product pipeline has entered the fast track of development. The company has fully implemented the strategic planning of FlashBot vascular interventional surgical robot, expanded the domestic and overseas marketing network of its commercialized product caFFR system, and promoted the large-scale clinical study of its commercialized product caIMR system. Looking back to 2022, domestic and foreign clinical researchers of RainMed continue to explore the field of coronary precision diagnosis and treatment with enthusiasm, and have published nearly 20 scientific research papers in global academic conferences and top journals, making outstanding contributions to promoting clinical research, health management and patient prognosis. This paper summary selected 6 splendid research results, hoping to help you better understand the clinical value of the functional diagnostic products independently developed by RainMed Medical.

01 caIMR System Can Predict Microvascular Dysfunction in Patients with Acute Myocardial Infarction After Surgery

Despite restoration of epicardial coronary blood flow by primary percutaneous coronary intervention (PCI) in patients with acute ST-segment elevation myocardial infarction (STEMI), failure of myocardial reperfusion can occur in up to two-thirds of STEMI patients, which is attributed to the occurrence of coronary microcirculatory dysfunction and microvascular obstruction(MVO). Therefore, assessment of microcirculatory dysfunctionand MVO after primary PCI would be important to evaluate the efficacy of the reperfusion therapy and need for potential further treatments.

On March 3, 2022, a team led by Professor Joo Myung Lee from Samsung Medical Center in South Korea published an article in JCR Q1 Revista Española de Cardiología comparing RainMed’s caIMR system with cardiac magnetic resonance (CMR). RainMed’s caIMR system was proven to be able to independently predict microvascular obstruction in patients with myocardial infarction after PCI, and the caIMR system, by contrast, was superior to CMR in clinical applicability.

For patients with coronary heart disease after PCI, caIMR system can be used to effectively assess blood flow recovery and improve the quality of prognosis. As the world's first non-invasive IMR measurement product to enter the confirmatory clinical trial, this study will provide further scientific evidence for clinical adoption of caIMR system.

Read the paper: https://www.sciencedirect.com/science/article/abs/pii/S1885585722000147?via%3Dihub

02 caFFR-Guided Functional SYNTAX Score Will Improve the Differentiation of Ventricular Tachycardia/Fibrillation Development in Patients With Acute Myocardial Infarction

Ventricular tachycardia/ventricular fibrillation (VT/VF) is one of the most severe complications in patients with acute myocardial infarction (AMI). Although many recent studies have described the risk factors for VT/VF after AMl, the relationship between the severity of coronary artery disease(CAD) and the occurrence of VT/VF in patients with AMl remains unclear. The SYNTAX score (SS) is an anatomical scoring system that indicates the severity of coronary artery lesions according to the number of lesions, their functional role, location, and complexity. However, in many cases, the anatomic lesion severity does not match the coronary physiology using fractional flow reserve (FFR). Therefore, SS, based solely on anatomical information, may lead to an erroneous assessment of lesion complexity, limiting the discriminant ability of the SS. Thus, in 2011, the concept of the functional SS (FSS) was developed.

On April 12, 2022, Professor Jiancheng Xiu's team from Nanfang Hospital of Southern Medical University published an article in JCR Q2 Frontiers in cardiovascular medicine. 705 patients were measured FSScaFFR with the guidance of caFFR system and conventional SS respectively. Comparison showed that FSScaFFR was demonstrated to be an independent correlation factor of incident VT/VF after AMI, and FSS was significantly superior to SS in differentiating results.

These findings suggest that patients with high FSScaFFR should be vigilant about the occurrence of VT/VF, and timely intervention measures should be taken in clinical practice for prevention. Therefore, caFFR can be used as an innovative functional indicator to better guide clinical practice, reduce the incidence of VT and VF, and improve the outcome of patients with AMI.

Read the paper: https://www.frontiersin.org/articles/10.3389/fcvm.2022.807805/full

03 Measuring caFFR immediately after Stenting Can Improve the Prognostic Value

The existence of untreated hemodynamically significant stenosis can hardly be found by post-stenting angiography, resulting in MACE recorded in more than 20% of the patients in two-year follow-up after PCI. Better tools for evaluating post-PCI coronary physiology are consistently needed. FFR immediately measured after stenting seems a good choice.

On May 21, 2022, Professor Yanjun Gong’s team from Peking University First Hospital published a paper in the JCR Q2 Frontiers in cardiovascular medicine to further explore the effects of caFFR measurement after PCI and the caFFR gradient across stents on the prognosis of patients. The results showed that caFFR gradient was not ideal immediately after PCI and was common in vessels after stent implantation. The lower the caFFR value after PCI, the higher the incidence of target vessel revascularization failure. After LAD PCI, both post-PCI caFFR and its gradient across stent were independent predictors of the neointimal proliferation of the target vessel evaluated by LLL and %DS at follow-up.

Due to technical and economic facts, the current application of functional evaluation of blood flow after PCI is not sufficient. More simplified techniques can facilitate functional evaluation after PCI. caFFR system can meet this requirement and further improve patient prognosis.

Read the paper: https://www.frontiersin.org/articles/10.3389/fcvm.2022.834553/full